PrintFriendly

Print Friendly, PDF & Email

CME/CPE Symposium for Specialty Pharmacy and Managed Care Professionals

April 22, 2016
CME/CPE Symposium for Specialty Pharmacy and Managed Care Professionals

Announcing the fourth Annual National Hemophilia Foundation Annual Meeting Pre-Conference Symposium, Enhancing the Value of Managed Care and Specialty Pharmacy within the Hemophilia Comprehensive Care Model

The National Hemophilia Foundation (NHF) and Impact Education, LLC (IMPACT) are pleased to announce  the  fourth annual pre-conference symposium specifically designed for specialty pharmacists, home health pharmacists, health plan pharmacists, managed Medicaid pharmacists, medical directors and other healthcare professionals with an interest in the management of patients with hemophilia. This free, CME/CPE-certified activity is scheduled to take place on Thursday, July 21, 2016, from 1:45 pm–5:00 pm at the Gaylord Palms Resort & Convention Center in Orlando, Florida, in conjunction with NHF’s 68th Annual Meeting, “A Brighter Future Together.”

Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for patients with the severest form. Optimal outcomes require a collaborative and coordinated patient experience. The collaborative team can include an insurer, hemophilia treatment center (HTC) and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans and employers in meeting clinical and/or financial goals.

This symposium features a multidisciplinary expert panel, including a specialty pharmacist expert, leading hematologist, HTC nurse coordinator and managed care pharmacy director. The program will provide an advanced clinical update. It will emphasize the need for well-coordinated treatment management, best practices to integrate hemophilia care with payer policies and the value of collaboration among all stakeholders.

Register today! Space is limited. The symposium is jointly provided by NHF, IMPACT and the Postgraduate Institute for Medicine. It is supported by independent educational grants from Baxalta US, Inc., Grifols and Novo Nordisk, Inc.